论文部分内容阅读
目的研究全球领先制药公司阿斯利康(AstraZeneca)知识产权保护制度的成功经验,为国内制药行业的发展特别是在新药创制方面提供借鉴。方法利用中外专利搜索引擎Soopat数据库和中国医药经济信息网,检索分析2000~2010年阿斯利康在全球及北美(美国和加拿大)、日本、中国的专利产出与经济效益的相关性。结果阿斯利康全球年专利申请累计数与年销售收入有显著线性正相关,在北美和日本也成线性正相关,但在中国其线性相关不显著;2006~2010年阿斯利康全球以及北美和日本地区年销售增长率随着专利申请量降低而减少(正相关),而在中国年销售增长率随着专利申请量增长而减少(负相关)。结论阿斯利康对知识产权的重视程度,直接影响其经济效益;阿斯利康在市场经济发达地区的稳健发展,得益于对知识产权的创造、运用和管理;阿斯利康在市场经济欠发达地区的快速发展,得益于专利的布局和技术转移。可见,新药创制和知识产权保护是医药企业发展的核心动力。
Objective To study the successful experience of AstraZeneca’s intellectual property protection system, the world’s leading pharmaceutical company, and provide references for the development of the domestic pharmaceutical industry, especially for the creation of new drugs. Methods Using the Chinese and foreign patent search engine Soopat database and Chinese medical economy information network, the correlation between patent output and economic benefits of AstraZeneca in global and North America (USA and Canada), Japan and China from 2000 to 2010 was analyzed. Results AstraZeneca’s global annual cumulative number of patent applications had a significant linear positive correlation with annual sales revenue, a linear positive correlation between North America and Japan, but no significant linear correlation between China and AstraZeneca. AstraZeneca’s global and North American and North American The annual sales growth rate in Japan decreased as the number of patent applications decreased (positive correlation) while the annual growth rate of sales in China decreased (negatively correlated) as the number of patent applications increased. Conclusion AstraZeneca’s emphasis on intellectual property rights has a direct impact on its economic benefits. AstraZeneca’s steady growth in developed market economies has benefited from the creation, application and management of intellectual property rights. In the underdeveloped market of AstraZeneca, The rapid development of the region, thanks to the layout of patents and technology transfer. Can be seen that the creation of new drugs and intellectual property protection is the core motive force for the development of pharmaceutical companies.